Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering

News
2026
2025
Archive
Search news articles

August 7, 2026

Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
August 7, 2026

CAMP4 advances rare disease treatment for SYNGAP1 into human trials
July 28, 2026

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 23, 2026

Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma
July 23, 2026

Nouscom Selected for Oral Presentation on NOUS-209 Re-Treatment and Long-Term Follow-up in Lynch Syndrome Carriers at ESMO Congress 2026
June 10, 2026

Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026
May 19, 2026

NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress
May 8, 2026

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
May 8, 2026

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 7, 2026

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

1
2
3
…
130
Next Page »